Risk factors for retinopathy associated with interferon α-2b and ribavirin combination therapy in patients with chronic hepatitis C

Table 1 Profiles and initial laboratory data of patients with and without retinopathy during IFN-ribavirin combination therapy¹

	Total	Retinopathy(+)	Retinopathy(-)
Patients
Number	73	14	59
Age (yr)	53.4 ± 10.9	56.3 ± 10.5	52.8±38.6
Gender (M/F)	47/26	10/4	37/22
Hypertension (Yes/No)a	15/58	5/8	10/49
Diabetes mellitus (Yes/No)	2/71	1/13	1/58
Peripheral blood count
Platelet count (×104/mm3)	15.3 ± 6.0	12.5 ± 10.5	15.9 ± 38.6
White blood cell (×103/mm3)	46.9 ± 12.6	46.5 ± 13.0	48.6 ± 10.9
Hemoglobin (×g/dL)	14.0 ± 1.3	14.0 ± 1.0	14.0 ± 1.4
Prothrombin time (%)	90.2 ± 13.3	87.1 ± 13.3	90.8 ± 13.3
ALT (IU/L)	109.4 ± 78.2	104.1 ± 41.0	110.4 ± 83.6
Viral factors
Genotype (type 1/type 2)2	45/26	33/24	12/2
Viral load (kcopies/mL)	592.3 ± 271.2	505.6 ± 309.1	607.5 ± 271.2
Pretreatment/ Arteriosclerotic	12/61	7/7	5/54
changes in optic fundi (Yes/No)
Response to therapy (SVR/non-SVR)	38/35	5/9	33/26

¹ Data are expressed as mean ± SD.

² Genotype could not be determined in 2 patients.

^aP = 0.004